{
  "claim_id": "claim_002",
  "claim": "Cell- and egg-based flu vaccines have the potential to develop mutations during production, which may reduce their effectiveness.",
  "document": {
    "pdf_name": "Hsiao_et_al.__2023_",
    "source_pdf": "data/clinical_files/Hsiao et al. (2023).pdf",
    "total_pages": 11,
    "total_blocks": 147,
    "total_characters": 24458
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 2,
    "error": null
  },
  "extracted_evidence": [
    {
      "id": 1,
      "quote": "BACKGROUND Quadrivalent recombinant influenza vaccines contain three times the amount of hemagglutinin protein as standard dose egg based vaccines, and the recombinant formulation is not susceptible to antigenic drift during manufacturing.",
      "relevance_explanation": "This quote explicitly states that recombinant vaccines are not susceptible to antigenic drift during manufacturing, implying that egg-based vaccines are susceptible to such drift, which can lead to mutations that may reduce effectiveness."
    },
    {
      "id": 2,
      "quote": "The effectiveness of standard dose vaccines - especially against the influenza A H3N2 subtype - may be attenuated by antigenic drift during egg based manufacturing, whereas the recombinant vaccine is not susceptible to such drift.",
      "relevance_explanation": "This quote directly supports the claim by stating that antigenic drift (mutations) can occur during egg-based vaccine manufacturing, potentially reducing vaccine effectiveness, while recombinant vaccines do not have this issue."
    }
  ],
  "model_used": "gpt-4.1"
}